{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:07:51Z","timestamp":1780304871688,"version":"3.54.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019081","name":"Science and Technology Program of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019081","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.transproceed.2025.07.027","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T09:34:37Z","timestamp":1757756077000},"page":"1589-1596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Efficacy and Safety of a Modified Conditioning Regimen Reducing the Dosage of Busulfan and Adding Thiotepa in Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1479-6736","authenticated-orcid":false,"given":"Na","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mincui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyong","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyang","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benshan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.transproceed.2025.07.027_bib0001","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2013-02-484097","article-title":"Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: Results from Study AML-BFM 2004\u0f3bJ\u0f3d","volume":"122","author":"Creutzig","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transproceed.2025.07.027_bib0002","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.2009.22.9088","article-title":"Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial\u0f3bJ\u0f3d","volume":"28","author":"Burnett","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.transproceed.2025.07.027_bib0003","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bmt.2017.3","article-title":"Allogeneic stem cell transplantation for refractory acute myeloid leukemia in pediatric patients: the UK experience\u0f3bJ\u0f3d","volume":"52","author":"Hare","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.transproceed.2025.07.027_bib0004","first-page":"802","article-title":"[Chinese expert consensus of the allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia (not APL) (2022)]","volume":"43","year":"2022","journal-title":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi"},{"issue":"18","key":"10.1016\/j.transproceed.2025.07.027_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13184536","article-title":"Advances in the first line treatment of pediatric acute myeloid leukemia in the polish pediatric leukemia and lymphoma study group from 1983 to 2019","volume":"13","author":"Czoga\u0142a","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.transproceed.2025.07.027_bib0006","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood.V89.11.3951","article-title":"Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation","volume":"89","author":"Nagler","year":"1997","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transproceed.2025.07.027_bib0007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/bmt.2016.239","article-title":"Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT","volume":"52","author":"Eder","year":"2017","journal-title":"Bone marrow transplantation"},{"issue":"13","key":"10.1016\/j.transproceed.2025.07.027_bib0008","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1182\/blood-2010-01-261800","article-title":"A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia","volume":"116","author":"Niewerth","year":"2010","journal-title":"Blood"},{"issue":"S1","key":"10.1016\/j.transproceed.2025.07.027_bib0009","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5045\/br.2020.S002","article-title":"Treatments for children and adolescents with AML","volume":"55","author":"Kim","year":"2020","journal-title":"Blood research"},{"issue":"9","key":"10.1016\/j.transproceed.2025.07.027_bib0010","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.21873\/anticanres.15951","article-title":"Improved outcome in pediatric acute myeloid leukemia: progress with hematopoietic cell transplantation","volume":"42","author":"Stankiewicz","year":"2022","journal-title":"Anticancer research"},{"key":"10.1016\/j.transproceed.2025.07.027_bib0011","doi-asserted-by":"crossref","first-page":"4056","DOI":"10.1182\/blood-2012-11-468348","article-title":"MRD-directed risk stratification treatment may improve outcomes of t (8;21) AML in the first complete remission: results from the AML05 multicentertrial\u0f3bJ\u0f3d","volume":"121","author":"Zhu","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transproceed.2025.07.027_bib0012","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1186\/s12885-020-07043-5","article-title":"Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t (8;21) acute myeloid leukemia in first remission based on MRD- guided treatment\u0f3bJ\u0f3d","volume":"15","author":"Hu","year":"2020","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.transproceed.2025.07.027_bib0013","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1016\/j.clml.2020.09.004","article-title":"Efficacy of haploidentical hematopoietic stem cell transplantation compared with chemotherapy as postremission treatment of children with intermediate- risk acute myeloid leukemia in first complete remission\u0f3bJ\u0f3d","volume":"21","author":"Xue","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.transproceed.2025.07.027_bib0014","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","article-title":"The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update[J]","volume":"14","author":"Zhang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.transproceed.2025.07.027_bib0015","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1182\/blood-2013-10-535716","article-title":"Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens","volume":"123","author":"Bitan","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.transproceed.2025.07.027_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13397","article-title":"Unrelated donor hematopoietic stem cell transplantation for pediatric de novo acute myeloid leukemia with intermediate- or high-risk cytogenetics","volume":"23","author":"Park","year":"2019","journal-title":"Pediatric transplantation"},{"issue":"7","key":"10.1016\/j.transproceed.2025.07.027_bib0017","doi-asserted-by":"crossref","first-page":"e1033","DOI":"10.1097\/MPH.0000000000002030","article-title":"Haploidentical stem cell transplantation with post-transplant cyclophosphamide for pediatric acute leukemia is safe and effective","volume":"43","author":"Sharma","year":"2021","journal-title":"J Pediat hematol\/Oncol"},{"issue":"7","key":"10.1016\/j.transproceed.2025.07.027_bib0018","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.bbmt.2019.02.025","article-title":"Thiotepa, busulfan, and fludarabine conditioning regimen in T cell-replete HLA-haploidentical hematopoietic stem cell transplantation","volume":"25","author":"Dul\u00e9ry","year":"2019","journal-title":"Biol Blood Marrow Transplant: Journal of the American Society for Blood and Marrow Transplantation"},{"issue":"3","key":"10.1016\/j.transproceed.2025.07.027_bib0019","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/10428194.2018.1510495","article-title":"Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity","volume":"60","author":"Sheth","year":"2019","journal-title":"Leukemia lymphoma"},{"issue":"6","key":"10.1016\/j.transproceed.2025.07.027_bib0020","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transproceed.2025.07.027_bib0021","doi-asserted-by":"crossref","first-page":"220","DOI":"10.18632\/oncotarget.28563","article-title":"ABT199\/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells","volume":"15","author":"Valdez","year":"2024","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.transproceed.2025.07.027_bib0022","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1038\/sj.bmt.1705863","article-title":"Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up","volume":"40","author":"Bacigalupo","year":"2007","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525004373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041134525004373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:36:35Z","timestamp":1780302995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041134525004373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0041134525004373"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.07.027","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Efficacy and Safety of a Modified Conditioning Regimen Reducing the Dosage of Busulfan and Adding Thiotepa in Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}